Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very quick look suggests they are focused on lung delivery rather than nasal.
Lots of companies have PMDI, DPI or NEB's technology so busy field.
Results out next week - diabetes chronic condition so recurring revenue but covid might have reduced patient acquisition.
Rorkesdrift / busymomof3
some more infos here: https://mannkindcorp.com/partnering/
Hi,
what do you think about to combine with Mannkinds Technosphere Inhaler (Freamboat).
Mannkind (MNKD) itself offers Tech Inhaler for diabetes (Afrezza), and United Therapeutics (UTHR) is in Phase III for inahlable Treprostinil (Tyvaso) using Technosphere Inhaler.
With the very new blue Hale Inhaler from Mannkind you can exactly see the amunt of drug directly goes to the lungs.
I would like to hear your opinion - I'm pretty sure that neither MNKD knows of Tmab nor knows TILS from Blue Hale Inhaler.
More infos: https://www.healthline.com/diabetesmine/bluhale-tech-and-afrezza#1
Hi Busymum
Not sure about the points you make. I'll try and respond to each but in my mind if you induce tolerance to a Tx organ fantastic. If you induce tolerance to a pathogenic organism, probably not so good. The scientists seem to be very clever so I'm trying to find where I'm getting it wrong - not them.
I know the arguments for and against animal testing. Hoping we don't need to go there.
I don't think the data from animal work is trying to lay down a future protocol for humans. MMF great drug as are steroids and tacrolimus. Narrow therapeutic windows, difficult compliance, long term sequalae.
I think what the suggestion is and I may be wrong if if you allow an immune response to happen then giving CD3 antibodies you induce tolerance in the immune cells that are reacting. If you treat before the immune response then the tolerance is not induced but you do suppress the immune response like you do with mmf albeit for much longer.
You are right in saying no doctor would do in humans what they did in these animal studies.
They are suggesting that do the Tx. Allow an initial immune response, treat with anti CD3, induce tolerance, remove the need for life long immunosuppression.
rorkes, i see what this paper is saying and yeah its amazing but please nobody take offence, look most products are tested on animals and the loss of life in animals is seen as a means to an end, So you try any find a Dr thats going to wait 7 days to start anti-rejecton drugs, i my opinion thats not going to happen there are not enough organs for transplant now , never mind hoping the organ can last the 7 days, average operation time is 7hrs, average ICU is 4 days, look if i am wrong on this its a bonus for me, as the most used anti-rejection drug on the market now is MMF and its a life long needed medication, what you have posted it says day 7 posttransplant in this particular model, about 85% of the recipients accepted their grafts indefinitely. to get this to human trial well.....people will say do it, if it means the organ isnt rejected, but from onset of liver failure you have 42 days before you die, and in that time you have to find a match and we all know, its not that easy to find a match, thats why the use of a living donor is on the rise, for me your post is dammed if i do dammed if i dont. And in all fairness its all about getting the drug to human trial. For now this is nothing that TILS is looking at, so sorry everyone for the posts as its not relevant to Tils.
From different paper
Using an islet transplant model (islets from BALB/c mice grafted under the kidney capsule of C57BL/6 recipients rendered diabetic following administration of streptozotocin), we showed that the short (5 days) CD3 antibody treatment applied at the time of transplantation (e.g., while no activation of alloreactive cells is present) significantly delayed rejection (42 days in treated mice versus 18 days in controls) yet all grafts were eventually rejected. Thus, only immunosuppression had been induced. In contrast, if the treatment was delayed once activation of alloreactive cells had occurred, day 7 posttransplant in this particular model, about 85% of the recipients accepted their grafts indefinitely.
Apologies when I say induction of tolerance it refers to transplant. Using these drugs means foreign organs are better tolerated - im trying to work out how long that tolerance lasts.
I'm thinking the nasal dosing is utilising the fact its a mucosal membrane. Immune response here then provokes changes across the body. The T-cells it changes are distributed across the body. Not sure that squirting it up your nose gets it into the lungs.
The oral version was the one used in trials and again the immune response happens locally but extends body wide.
That's my interpretation but don't know enough about it.
tolerance is the main problem for the mabs which i have posted before, the problem is you build up antibody resistance to the medication, the mabs are made from 20% mouse protein you also have to take immune suppressants (daily maintenance chemo) you have to have regular tests to check the antibody levels, and once you have built up resistance there is no going back, you have to change medication, mabs are all injections or intravenous infusion you also have to wait after the infusion/injection to make sure you have no side effects from the medication, but Foralumab is fully-human and oral you wont have that problem this is why its so life changing, these autoimmune diseases take away quality of life and reduce life expediency.
ok the nasal dosing say you have a piece of string and you put some water at one end, you hold that end up and you see how much water reaches the dry end thats what is happening now or what Tils is saying you just put it straight into the lungs so which one would you choose.
Good spot. Wish I understood half of it. I cannot work out if inducement of tolerance is permanent or only whilst on drug.
So 4 CD3 products in development and we have the best tolerated.
I was trying to work out how systemic effect from nasal dosing happens
so rokes have you seen who has co written this paper.......our own BOD member Dr Howard L Weiner